IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30...